Reports Q4 revenue $103.06M, consensus $105.08M . Fourth quarter diluted net income per common share of $0.14, compared to $0.26 in fourth quarter 2021.Cash and investments of $436.6 million at December 31, 2022 compared to $335.8 million at December 31, 2021."We remain extremely optimistic about the growth potential of our Cushing’s syndrome business. Korlym is an excellent treatment for patients with Cushing’s syndrome and there are many eligible patients who have yet to receive it. We are making substantial investments to improve the screening and treatment of these patients. We are providing 2023 revenue guidance of $430 – $450 million," said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CORT:
- Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update
- Corcept downgraded to Hold at Jefferies ahead of 2023 guidance
- Corcept Therapeutics downgraded to Hold from Buy at Jefferies
- Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation